Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 10/20 | 0.39 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19706172 | 0.87 | IDH2 (0.40) | IDH2MAPTBTKKDM1AKDM4E | |
| SCHEMBL16250010 | 0.83 | CA2 (0.42) | IDH2MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL16238734 | 0.82 | CA2 (0.41) | IDH2MAPTBTKKDM4E | |
| SCHEMBL19706045 | 0.81 | IDH2 (0.35) | IDH2SPHK2SPHK1KDM1ACNR2 | |
| SCHEMBL19670200 | 0.80 | FAAH (0.36) | IDH2BTKKDM4E | |
| SCHEMBL19706685 | 0.80 | IDH2 (0.41) | IDH2KDM1ACNR2 | |
| SCHEMBL19706975 | 0.79 | IDH2 (0.36) | IDH2KDM1A | |
| SCHEMBL19706095 | 0.79 | CHRM3 (0.41) | IDH2CNR2 | |
| SCHEMBL17618878 | 0.79 | IDH2 (0.42) | IDH2MAPTKDM4E | |
| SCHEMBL19706914 | 0.78 | IDH2 (0.38) | IDH2KDM1ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | IDH2 34/4885SPHK2 2797/4885SPHK1 2548/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | IDH2 34/4885SPHK2 2797/4885SPHK1 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.